What is the 13F Pro Quality Score for EOLS?

13F Pro ranks Evolus, Inc. (EOLS) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View EOLS's current score at https://13fpro.ai/research/EOLS (free sign-up required for the full ranking).

Which hedge funds own the most EOLS stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of EOLS include Nantahala Capital Management,, BlackRock,, BRAIDWELL. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/EOLS as soon as new 13F filings post.

Where does 13F Pro source EOLS data?

All Evolus, Inc. fundamentals and ownership data come directly from SEC EDGAR. Evolus, Inc. files with the SEC under CIK 1570562. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is EOLS in?

Evolus, Inc. (EOLS) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is EOLS research updated on 13F Pro?

EOLS's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Evolus, Inc.(EOLS)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1570562 EOLS stock profile & AI dashboard →

13F Pro Quality Score

30.0/100

Rank #2,375 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

79.5/100

Profitability

16.8/100

Balance Sheet

8.1/100

Earnings Quality

30.0/100

Free Cash Flow

12.9/100

Institutional Flow

15.4/100

Revenue Scale

28.5/100

Dilution Risk

21.4/100

EOLS Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Evolus, Inc. (EOLS), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores EOLS at 30.0/100 on a 32-signal composite quality model, placing it at rank #2,375 of 2,879 stocks — the bottom half of the AI-ranked universe. EOLS scores in the top quartile across revenue growth (79.5). Areas of concern include balance sheet strength (8.1) and free cash flow (12.9), which score below median versus the broader universe. Shareholder dilution risk is elevated at 21.4/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), Evolus, Inc. reports quarterly revenue of $73.1M, net income of $-10.7M, an operating margin of -9.4%. Top institutional holders of EOLS by reported 13-F value include Nantahala Capital Management,, BlackRock,, BRAIDWELL, based on the most recent SEC filings. EOLS trades on the Nasdaq exchange and files with the SEC under CIK 1570562. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate EOLS daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Evolus, Inc. directly from SEC EDGAR. Evolus, Inc.'s 13F Pro composite quality score has ranged between 8 and 68 since 2021, currently 30.0 — a stable long-term trajectory across 56 quarterly and live scoring snapshots.

✦

Fun facts about Evolus, Inc.

Quirks, history, and lore behind EOLS — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. specialty pharmaceutical company · listed on Nasdaq · focused on the medical aesthetics market · headquartered in Southern California.
2
The Numbers
A small-cap company with annual revenue in the low hundreds of millions of dollars, still working toward consistent profitability as it builds out its commercial infrastructure.
3
The History
Founded in 2012 with a singular mission: take on the entrenched giant of the neurotoxin injection market and carve out a meaningful slice of a multi-billion-dollar aesthetic category.
4
The Secret
Its core product is a botulinum toxin type A — the same class of injectable as its dominant rival — but it's positioned as a performance neurotoxin aimed squarely at aesthetic injectors who want an alternative.
5
The Lore
The company licenses its technology from Daewoong Pharmaceutical in South Korea, which touched off a high-profile legal battle with Medytox and Allergan over alleged trade-secret theft.
6
The Giveaway
Its injectable neurotoxin brand Jeuveau — nicknamed #NEWTOX — is the only FDA-approved botulinum toxin launched in the U.S. in nearly a decade when it hit the market in 2019.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q1 2026

$73.1M

Net Income

Q1 2026

$-10.7M

Free Cash Flow

Q1 2026

$-10.4M

Operating Margin

Q1 2026

-9.4%

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+49.1% YoY

$148.6MFY 2022

FY16 —FY20 $56.5MFY21 $99.7MFY22 $148.6M

Net Income

-59.0% YoY

$-74.4MFY 2022

FY16 —FY20 $-163.0MFY21 $-46.8MFY22 $-74.4M

Operating Income

-47.1% YoY

$-65.3MFY 2022

FY16 —FY20 $-153.1MFY21 $-44.4MFY22 $-65.3M

EPS (Diluted)

-41.5% YoY

$-1.33FY 2022

FY16 —FY20 $-4.83FY21 $-0.94FY22 $-1.33

Total Assets

-30.9% YoY

$178.0MFY 2022

FY16 —FY20 $209.1MFY21 $257.5MFY22 $178.0M

Total Debt

+0.9% YoY

$71.9MFY 2022

FY16 —FY20 —FY21 $71.2MFY22 $71.9M

Op. Cash Flow

-154.3% YoY

$-84.9MFY 2022

FY16 —FY20 $-57.9MFY21 $-33.4MFY22 $-84.9M

Metric	FY 2022	FY 2021	FY 2020	FY 2016
Revenue	$148.6M +49.1%	$99.7M +76.3%	$56.5M	—
Net Income	$-74.4M -59.0%	$-46.8M +71.3%	$-163.0M	—
Operating Income	$-65.3M -47.1%	$-44.4M +71.0%	$-153.1M	—
EPS (Diluted)	$-1.33 -41.5%	$-0.94 +80.5%	$-4.83	—
Total Assets	$178.0M -30.9%	$257.5M +23.2%	$209.1M	—
Total Debt	$71.9M +0.9%	$71.2M	—	—
Operating Cash Flow	$-84.9M -154.3%	$-33.4M +42.3%	$-57.9M	—

AI Insight: EOLS Financial Trends

Evolus achieved breakeven profitability in Q4 2025 but immediately returned to losses in Q1 2026, while debt increased 29% over two years.

• Revenue grew from $67M in Q2 2024 to $73M in Q1 2026, with Q4 quarters showing seasonal strength at $79M and $90M.

• Company reached breakeven with $0M net income in Q4 2025, the only profitable quarter in the dataset.

• Total debt increased from $121M in Q2 2024 to $156M in Q1 2026, rising 29% over eight quarters.

• Equity deteriorated from $19M in Q2 2024 to negative $29M in Q1 2026, reflecting persistent losses.

⚠ Operating cash flow swung from $13M positive in Q4 2025 back to negative $10M in Q1 2026.

⚠ Q4 seasonal revenue spikes appear unsustainable as Q1 2026 revenue fell 19% sequentially to $73M.

AI Insight: EOLS Ratio Trends

Evolus showed profitability in Q4 2025 with 4.7% operating margin but immediately returned to losses in Q1 2026.

• Operating margin improved dramatically from -22.1% in Q1 2025 to 4.7% in Q4 2025 before declining to -9.4% in Q1 2026.

• ROIC swung from deeply negative -52.7% in Q1 2025 to positive 13.7% in Q4 2025 then back to -21.5% in Q1 2026.

• Company achieved positive net margin of 0.1% in Q4 2025, the only profitable quarter in the data series.

⚠ Profitability appears highly volatile with sharp swings between quarters, suggesting operational instability or seasonality issues.

⚠ Return to double-digit operating losses in Q1 2026 after brief Q4 2025 profitability raises sustainability concerns.

Get alerted when EOLS's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Evolus, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of EOLS

Nantahala Capital Management, LLC
$26.2M6,376,857 sh
BlackRock, Inc.
$17.6M4,290,383 sh
BRAIDWELL LP
$12.8M3,105,209 sh
Frazier Life Sciences Management, L.P.
$10.8M2,630,665 sh
VANGUARD CAPITAL MANAGEMENT LLC
$10.2M2,470,408 sh
Soleus Capital Management, L.P.
$9.2M2,245,360 sh
Stonepine Capital Management, LLC
$7.2M1,759,091 sh
MILLENNIUM MANAGEMENT LLC
$6.0M1,461,159 sh
ARMISTICE CAPITAL, LLC
$5.7M1,396,000 sh
GEODE CAPITAL MANAGEMENT, LLC
$5.7M1,381,338 sh

Fund	Value	Shares
Nantahala Capital Management, LLC	$26.2M	6,376,857
BlackRock, Inc.	$17.6M	4,290,383
BRAIDWELL LP	$12.8M	3,105,209
Frazier Life Sciences Management, L.P.	$10.8M	2,630,665
VANGUARD CAPITAL MANAGEMENT LLC	$10.2M	2,470,408
Soleus Capital Management, L.P.	$9.2M	2,245,360
Stonepine Capital Management, LLC	$7.2M	1,759,091
MILLENNIUM MANAGEMENT LLC	$6.0M	1,461,159
ARMISTICE CAPITAL, LLC	$5.7M	1,396,000
GEODE CAPITAL MANAGEMENT, LLC	$5.7M	1,381,338

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put EOLS on your watchlist

Track score changes the day Evolus, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is EOLS a good stock to buy?

13F Pro's AI-powered analysis of Evolus, Inc. (EOLS) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for EOLS are available on the EOLS stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own EOLS?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling EOLS. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Evolus, Inc.'s investment landscape.